{"id":"https://genegraph.clinicalgenome.org/r/8058f392-72ea-48e8-8968-a5f7c40cc62dv1.0","type":"EvidenceStrengthAssertion","dc:description":"","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/8058f392-72ea-48e8-8968-a5f7c40cc62d","GCISnapshot":"https://genegraph.clinicalgenome.org/r/70af8ffa-430b-4c69-bfa9-d6ba2f7b4f32","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/70af8ffa-430b-4c69-bfa9-d6ba2f7b4f32_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10010","date":"2020-09-01T00:00:00Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/70af8ffa-430b-4c69-bfa9-d6ba2f7b4f32_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10010","date":"2018-06-26T16:00:00.000Z","role":"Approver"}],"curationReasonDescription":"","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/70af8ffa-430b-4c69-bfa9-d6ba2f7b4f32_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6ad380cb-2d51-4638-be10-f590fa05cf3d_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Decided on higher then default, points since there is a lot of evidence from patient-derived fibroblasts. (See variant evidence)","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9e4e9047-7326-43fb-9baf-84ee091d3955","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12955715","rdfs:label":"Mat1","ageType":"AgeAtDiagnosis","ageUnit":"Months","ageValue":7,"detectionMethod":"\"Polymerase chain reaction (PCR) amplification was used to amplify products that spanned the five MYLCD exons from genomic DNA (see Table 2 for primer sequences). The 50 region of exon 1 is very CG-rich and was amplified in two overlapping fragments. Exon 1 (50 region) was amplified using the Advantages-CG rich polymerase mix kit (Clontech, Palo Alto, CA), according to manufacturer’s instructions...\"","ethnicity":{"id":"cg:HispanicOrLatino"},"firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"High malonic acid, methylmalonic acid and ethylrnalonic acid in urine","phenotypes":["obo:HP_0001250","obo:HP_0001638","obo:HP_0001263"],"previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/6ad380cb-2d51-4638-be10-f590fa05cf3d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12955715","allele":{"id":"https://genegraph.clinicalgenome.org/r/64e21701-8fd7-4b1c-8f3b-75c5f587c78d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012213.2(MLYCD):c.119T>C (p.Met40Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/4060"}}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/514466f5-480e-428f-9efe-8d8c3f5f5471_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/eade44f4-ab25-4ec6-b1e3-280cf4c7b635","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12955715","rdfs:label":"Haa1","ageType":"AgeAtDiagnosis","ageUnit":"Months","ageValue":10,"detectionMethod":"","firstTestingMethod":"Genotyping","phenotypes":["obo:HP_0001942","obo:HP_0001250","obo:HP_0001943","obo:HP_0002013","obo:HP_0001263","obo:HP_0001941"],"previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/514466f5-480e-428f-9efe-8d8c3f5f5471_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12955715","allele":{"id":"https://genegraph.clinicalgenome.org/r/37312980-0ea2-496a-9d22-78f36bcd5fa0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012213.2(MLYCD):c.475delG (p.Ala159Profs)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/203813"}}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/ab844162-0579-4a0d-88e6-3e7ddb0f0be9_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Significant variant evidence.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c5553adb-26cc-43df-92a9-edfbdd2d9905","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12955715","rdfs:label":"Yan1","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":4,"detectionMethod":"PCR amplification was used to amplify products that spanned the five MYLCD exons from genomic DNA . Authors note that the 50 region of exon 1 is very CG-rich and addressed this by modifying the PCR protocol and amplifying the region in two overlapping fragments.","ethnicity":{"id":"cg:HispanicOrLatino"},"firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0001941","obo:HP_0001250","obo:HP_0001638","obo:HP_0001943","obo:HP_0002013","obo:HP_0001263","obo:HP_0001942"],"previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/ab844162-0579-4a0d-88e6-3e7ddb0f0be9_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12955715","allele":{"id":"https://genegraph.clinicalgenome.org/r/24396744-6b0b-4886-adec-271eabf24e01","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"MLYCD, 25-BP DEL, NT84","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/4061"}}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/adfd2e54-e9ed-481e-8e0e-dcceb98a0d4d_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5aec4c60-1cec-4e50-8d02-46b9fb7fce8d","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9869665","rdfs:label":"Gao 1999 Proband","ageType":"AgeAtOnset","ageUnit":"Days","ageValue":1,"detectionMethod":"Sanger sequencing of cDNA from primary patient fibroblasts. See Figure 3","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0001939","obo:HP_0001522","obo:HP_0001290","obo:HP_0004347","obo:HP_0012072","obo:HP_0000110","obo:HP_0001695","obo:HP_0001639","obo:HP_0001942","obo:HP_0000054"],"previousTesting":true,"previousTestingDescription":"Authors ruled out chromosomal abnormalities. Methods were not described.","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/adfd2e54-e9ed-481e-8e0e-dcceb98a0d4d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9869665","allele":{"id":"https://genegraph.clinicalgenome.org/r/b4cec6ba-d0a7-45b1-baf6-52c7798d91a3","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"MLYCD, 4-BP DEL, 638GTGA","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/4057"}}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/3e3e7486-a831-41ec-bc2e-f7f9c3017479_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Decided to score as a null variant, but gave lower than default since there is family consanguinity. The score could increase depending on expert review.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f36b0dec-f74d-4609-85d6-f0503c27d874","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12955715","rdfs:label":"San3","ageType":"AgeAtReport","ageUnit":"Years","ageValue":18,"detectionMethod":"PCR amplification was used to amplify products that spanned the five MYLCD exons from genomic DNA . Authors note that the 50 region of exon 1 is very CG-rich and addressed this by modifying the PCR protocol and amplifying the region in two overlapping fragments.","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"left-sided cerebral infarction, right-sided cerebral palsy, malonic aciduria","phenotypes":["obo:HP_0001263","obo:HP_0001433","obo:HP_0100021","obo:HP_0001531","obo:HP_0001941","obo:HP_0001942","obo:HP_0000047","obo:HP_0001250","obo:HP_0001943","obo:HP_0000023","obo:HP_0004322"],"previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/3e3e7486-a831-41ec-bc2e-f7f9c3017479_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12955715","allele":{"id":"https://genegraph.clinicalgenome.org/r/cc1f1cba-7ec6-427b-8bf0-e24ffe53fe4b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012213.2(MLYCD):c.1151_1159del (p.Trp384_Gln386del)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA658820585"}}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/2e437960-f76e-4913-8a3f-9bee4cd82122_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Decided to score based on high variant evidence but chose lower than the default score in recognition of family consanguinity.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8b30867a-7a21-4a2c-bb6a-3c646b5e8ce3","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12955715","rdfs:label":"Bro1","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":5,"detectionMethod":"","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0001263","obo:HP_0004322","obo:HP_0001941","obo:HP_0002027","obo:HP_0002013"],"previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/2e437960-f76e-4913-8a3f-9bee4cd82122_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12955715","allele":{"id":"https://genegraph.clinicalgenome.org/r/5d20b6af-972f-43bf-8e38-c17f92ff9449","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012213.2(MLYCD):c.8G>A (p.Gly3Asp)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/4059"}}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/7d75b102-b81c-433a-bbbf-975f493e31a4_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Consanguineous parents, only MLYCD was evaluated. Some supporting experimental evidence. Could score up to default depending on expert review.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/21716800-9354-4c8e-812c-b23ca37a61a0","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12955715","rdfs:label":"McP2","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":1,"detectionMethod":"PCR amplification was used to amplify products that spanned the five MYLCD exons from genomic DNA . Authors note that the 50 region of exon 1 is very CG-rich and addressed this by modifying the PCR protocol and amplifying the region in two overlapping fragments.","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0001263","obo:HP_0001943","obo:HP_0002013","obo:HP_0001942","obo:HP_0001250"],"previousTesting":true,"previousTestingDescription":"MLYCD was previously evaluated through direct PCR sequencing (FitzPatrick et al. 1999 PMID: 10417274)","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/7d75b102-b81c-433a-bbbf-975f493e31a4_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12955715","allele":{"id":"https://genegraph.clinicalgenome.org/r/6fdbb866-5b7c-413f-b593-335c8665e549","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012213.2(MLYCD):c.560C>G (p.Ser187Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/4055"}}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/97a1cbd9-0001-4f75-879b-29c0b6f43553_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8656990c-74a2-45c8-9912-940300020013","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12955715","rdfs:label":"San1","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":6,"detectionMethod":"PCR amplification was used to amplify products that spanned the five MYLCD exons from genomic DNA . Authors note that the 50 region of exon 1 is very CG-rich and addressed this by modifying the PCR protocol and amplifying the region in two overlapping fragments","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0001941","obo:HP_0001943","obo:HP_0001942","obo:HP_0001638","obo:HP_0001644"],"previousTesting":false,"previousTestingDescription":"","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/97a1cbd9-0001-4f75-879b-29c0b6f43553_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12955715","allele":[{"id":"https://genegraph.clinicalgenome.org/r/6b2a506a-5835-4769-828e-9403ddc7216f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012213.2(MLYCD):c.59dup (p.Arg21AlafsTer?)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA624017909"}},{"id":"https://genegraph.clinicalgenome.org/r/f13f398e-3874-4ab3-973a-83d3edd1ac80","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012213.2(MLYCD):c.634dup (p.Ile212AsnfsTer3)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA658820584"}}],"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/0020673c-e133-48a3-81a6-c1dcda2d3366_proband_score_evidence_line","type":"EvidenceLine","dc:description":"While there is experimental evidence to support the variant found in this patient, I decided to give this proband 0 pts due to discrepancies in the reported variant nomenclature, inconsistencies in phenotype-enzyme activity in previous reports as noted by current authors, parental consanguinity, and finally the uncertainty of variant relevance illuminated by gnomAD's description of \"non coding transcript exon\" for this (likely) variant while noting that the allelic variant c.949-8C>G is considered a splice region. The final decision for this variant will be determined by expert review.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7ce0e25a-e7c0-4bea-beb6-29bd668d6b4d","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12955715","rdfs:label":"McP1","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":4,"detectionMethod":"PCR amplification was used to amplify products that spanned the five MYLCD exons from genomic DNA . Authors note that the 50 region\nof exon 1 is very CG-rich and addressed this by modifying the PCR protocol and amplifying the region in two overlapping fragments.","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0001263","obo:HP_0002013","obo:HP_0001250"],"previousTesting":true,"previousTestingDescription":"MLYCD was previously evaluated through direct PCR sequencing (FitzPatrick et al. 1999 PMID: 10417274)","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/0020673c-e133-48a3-81a6-c1dcda2d3366_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12955715","allele":{"id":"https://genegraph.clinicalgenome.org/r/a892f5ea-e5fb-4408-b7cc-b91e36635af3","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"MLYCD, IVS4AS, A-G, -14","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/4056"}}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/598dd898-b39a-45ea-a60b-d7cde8d33e9c_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Consanguineous parents, but some variant level evidence","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8adc093a-2621-449d-adae-e51ebcce3cff","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12955715","rdfs:label":"Kra1","ageType":"AgeAtDiagnosis","ageUnit":"Days","ageValue":4,"detectionMethod":"PCR amplification was used to amplify products that spanned the five MYLCD exons from genomic DNA . Authors note that the 50 region of exon 1 is very CG-rich and addressed this by modifying the PCR protocol and amplifying the region in two overlapping fragments.","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0001941","obo:HP_0008947","obo:HP_0001942","obo:HP_0001263","obo:HP_0002240","obo:HP_0001943"],"previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/598dd898-b39a-45ea-a60b-d7cde8d33e9c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12955715","allele":{"id":"https://genegraph.clinicalgenome.org/r/e15c7eda-0886-45da-a8ca-db841fc2597e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012213.2(MLYCD):c.393C>G (p.Tyr131Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA396918242"}}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/70af8ffa-430b-4c69-bfa9-d6ba2f7b4f32_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/70af8ffa-430b-4c69-bfa9-d6ba2f7b4f32_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b89225fa-e973-4401-b22b-290b028e39c9","type":"EvidenceLine","dc:description":"Adding this model to this entry to note that a KO mouse model exists but that no phenotypes related to human malonic aciduria were noted.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ffffbaff-5481-44c6-a2e2-f84c035561b3","type":"Finding","dc:description":"Curating this model to note that no phenotype similar to human malonic aciduria was described in these mice. The authors were mainly focused on the potential cardiac phenotype but stated that \" Heterozygous and mcd−/− mice were produced with a near-mendelian frequency, and neither the heterozygous nor the mcd−/− mice displayed any overt phenotypes.\" It seems that no attempt to mimic or measure other metabolic phenotypes (i.e. stress test, fasting testing for aciduria) were made.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17030679","rdfs:label":"Malonyl coenzyme A decarboxylase KO mice","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/70af8ffa-430b-4c69-bfa9-d6ba2f7b4f32_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/aec02994-78ef-4615-9511-7d024eb99025","type":"EvidenceLine","dc:description":"Could mark down considering this evidence also supports most of the variants curated for this entry. Would like to avoid over counting, but there is no other study showing this level of protein evidence in patient cells. There are other genetic studies with additional probands and variants.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0e6dcedd-e2ba-4faf-95bb-4625309813d5","type":"FunctionalAlteration","dc:description":"mRNA: all patient cell-line mRNA was detectable and all but one were reduced compared to the control mRNA. The reduction ranges from 12.8%-94.2%. Cell-line San3 had markedly increase mRNA levels at 202.9% of controls. \n\nProtein Levels: six cell-lines showed no MCD protein on western blot analysis, three cell-lines showed a reduced level. One cell-Line showed a substantial increase in protein level at the expected  66 kDa band and an additional 67-83 kDa band. \n\nEnzyme activity: the enzyme activity was reduced in 9/10 cell-lines, the activity of the 10th cell-line was not determined. the reduced activity levels ranged from <3%-30.3%.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12955715","rdfs:label":"Cell-Line Protein Study"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/70af8ffa-430b-4c69-bfa9-d6ba2f7b4f32_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f864ae5e-1fff-4a1b-8b5e-e0d2b5368418","type":"EvidenceLine","dc:description":"I would consider scoring a 0.25 to recognize that this experiment does not have a strong connection back to patient phenotype.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/218246f8-7af9-46dc-a6c6-1b73220878fb","type":"Finding","dc:description":"The authors cite previous studies that report that malonic aciduria (an inborn error of metabolism) is caused by the loss of malonyl-CoA decarboxylase activity. The HPO for Abnormality of metabolism/homeostasis is consistent with the evidence of MCD's role in catalyzing malonyl-CoA to acetyl-CoA. This experiment specifically examined the ability of the suspected human MCD to bind to malonyl-CoA.  \n\nThe authors tired to find evidence of variation in the identified MLYCD gene in a patient. They found a variant (presumably heterzygous) c.947–948delTT in the patient, however this patient was reevaluated in  Wightman et al. 2003 (PMID:12955715) and was found to be homozygous for c.119T>C (p.Met40Thr). Wightman et al. were unable to confirm the c.947_948delTT variant.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10455107","rdfs:label":"Activity of human malonyl-CoA decarboxylase","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/405502f1-07fb-45ca-8875-9eab66241183","type":"EvidenceLine","dc:description":"We may want to down-score this evidence to to reflect that the authors did not explicitly connect this gene's function with the full patient phenotype (and were not able to at the time of publication).","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/88a05c40-b819-4807-8bb4-069eb2f054c5","type":"Finding","dc:description":"Malonyl CoA decarboxylase catalyzes the conversion of malonyl-CoA to acetyl-CoA and carbon dioxide. It is thought to be involved in aspects of fatty acid biosynthesis and oxidation. The detailed role of this enzyme in normal metabolism and an explanation for the full patient phenotype is not available in this paper and the score for this evidence might be downgraded to reflect this. However, it follows that changes in activity of this enzyme causes abnormalities in metabolism.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9869665","rdfs:label":"Gao 1991 Enzyme Expression/Activity (Biochemical Function)","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/40b3dcec-ddd4-4a5b-982e-62e83c63e526","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ade1f953-41b9-4d19-98d3-3f9c4b0615b6","type":"Finding","dc:description":"The Authors analyzed the expression of MCD mRNA in different human tissues. Multitissue Northern blots containing poly(A)+ RNA from 16 different tissues were hybridized with a radiolabeled MCD-specific probe (Fig.7). A 2.3-kilobase MCDtranscript was detected in all tissues examined. The abundance of the MCD mRNA varied, with extremely strong expression in cardiac and skeletal muscle. The levels of MCD mRNA were much lower in liver, kidney, and pancreas, and low but detectable in all other tissues. The expression specificity to heart tissue is significant given that several malonic aciduria patients have cardiomyopathy phenotypes.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10455107","rdfs:label":"Malonyl-CoA Decarboxylase Is Highly Expressed in Muscle","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":2.5}],"evidenceStrength":"Definitive","sequence":486,"specifiedBy":"GeneValidityCriteria6","strengthScore":14.5,"subject":{"id":"https://genegraph.clinicalgenome.org/r/zIBNBIi8Nys","type":"GeneValidityProposition","disease":"obo:MONDO_0009556","gene":"hgnc:7150","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_70af8ffa-430b-4c69-bfa9-d6ba2f7b4f32-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}